Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) unveiled promising results from its Open-Label Extension (OLE) study ...

We came across a bullish thesis on Harmony Biosciences Holdings, Inc. (HRMY) on Value Investing Subreddit Page by Long-Access-2143. In this article, we will summarize the bulls’ thesis on HRMY.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $58.31, a high ...

NEW YORK, NY / ACCESS Newswire / April 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the ...

Harmony Biosciences Stock Falls On FDA Setback For Pitolisant In Sleeping Disorder Harmony Biosciences' FDA setback for pitolisant in idiopathic hypersomnia doesn't impact its 2025 revenue outlook ...

Highlights,Teacher Retirement System of Texas significantly raised its position in Harmony Biosciences.,Additional hedge funds reported increased equity stakes during the same quarter.,The company ...

HRMY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

One company to watch right now is Harmony Biosciences (HRMY). HRMY is currently holding a Zacks Rank of #2 (Buy) and a Value grade of A. We should also highlight that HRMY has a P/B ratio of 3.27.

Shares of Harmony Biosciences HRMY have lost 10.8% in the past six months compared with the industry’s decline of 9.7%. The stock has also underperformed the S&P 500 index during this timeframe.